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Abstract
Patients with relapsed or refractory multiple myeloma have an immunosuppressive state with upregulation of
programmed death receptor-1 on immune effector cells. Treatment with daratumumab plus cetrelimab, which
targets the programmed death receptor-1, was evaluated in 9 patients with relapsed or refractory multiple
myeloma. No new safety concerns were identified for the combination. The potential clinical benefit of
daratumumab plus cetrelimab remains uncertain.
Background: Daratumumab is approved for relapsed or refractory multiple myeloma (RRMM) as monotherapy or in
combination regimens. We evaluated daratumumab plus cetrelimab, a programmed death receptor-1 inhibitor, in
RRMM. Patients and Methods: This open-label, multiphase study enrolled adults with RRMM with  3 prior lines of
therapy. Part 1 was a safety run-in phase examining dose-limiting toxicities of daratumumab (16 mg/kg intravenously
weekly for cycles 1-2, biweekly for cycles 3-6, and monthly thereafter) plus cetrelimab (240 mg intravenously biweekly,
all cycles). In Parts 2 and 3, patients were to be randomized to daratumumab with or without cetrelimab (same
schedule as Part 1). Endpoints included safety, overall response rate, pharmacokinetics, and biomarker analyses.
Results: Nine patients received daratumumab plus cetrelimab in the safety run-in, and 1 received daratumumab in
Part 2 before administrative study termination following a data monitoring committee’s global recommendation to stop
any trial including daratumumab combined with inhibitors of programmed death receptor-1 or its ligand (programmed
death-ligand 1). The median follow-up times were 6.7 months (safety run-in) and 0.3 months (Part 2). No dose-limiting
toxicities occurred. All 10 patients had  1 treatment-emergent adverse event; 7 patients had grade 3 to 4 treatment-
emergent adverse events, and none led to treatment discontinuation or death. In the safety run-in, 7 (77.7%) patients
had  1 infusion-related reaction (most grade 1-2), and 1 had a grade 2 immune-mediated reaction. Among safety run-
in patients, the overall response rate was 44.4%. Conclusions: No new safety concerns were identified for
daratumumab plus cetrelimab in RRMM. The short study duration and small population limit complete analysis of this
combination.
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Introduction
Survival has improved dramatically over the past 20 years for
patients with multiple myeloma (MM),1 owing in part to novel
treatment options including proteasome inhibitors (PIs), immuno-
modulatory agents (IMiDs), histone deacetylase inhibitors, and
monoclonal antibodies. However, MM remains incurable, and most
patients eventually experience progressive disease. The estimated
5-year survival rate for patients with newly diagnosed MM
(NDMM) is 52%,1 whereas patients with relapsed or refractory
multiple myeloma (RRMM) have poorer outcomes. Real-world
studies report median progression-free survival (PFS) times of 5 to
13 months2,3 and median overall survival (OS) of approximately 20
to 32 months among patients with RRMM that failed multiple lines
of therapy.3,4 Thus, there is an unmet need for more effective
therapies, particularly among patients with RRMM.
Daratumumab is a human IgG1k anti-CD38 monoclonal anti-
body approved as monotherapy for the treatment of RRMM and as
combination therapy for RRMM and NDMM.5 Daratumumab has
a direct on-tumor6-9 and immunomodulatory mechanism of ac-
tion.10-12 Daratumumab-induced on-tumor activity occurs through
several CD38 immune-mediated actions (complement-dependent
cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-
dependent cellular phagocytosis), apoptosis, and modulation of
CD38 enzymatic activity.6-9 Daratumumab induces an immuno-
modulatory effect that minimizes the immune-suppressive functions
of CD38þ myeloid-derived tumor suppressor cells (MDSCs), reg-
ulatory T cells (Tregs), and regulatory B cells and increases T-cell
clonality.10-12
In patients with MM, the immune checkpoint protein pro-
grammed death receptor-1 (PD-1) is upregulated on effector T cells
and natural killer (NK) cells, and the programmed death-ligand 1
(PD-L1) is expressed on malignant plasma cells.13,14 Overexpression
of PD-1 or PD-L1 creates an immunosuppressive microenviron-
ment associated with disease progression.13-15 For these reasons, the
role of PD-(L)1 in MM disease progression is of interest, as is the
therapeutic potential of PD-(L)1 blockade. Cetrelimab is a fully
human monoclonal IgG4k anti‒PD-1 antibody. In a phase I/II
study of cetrelimab in 192 patients with advanced or refractory solid
tumors, cetrelimab was well tolerated and had promising antitumor
activity, with 2 patients achieving a complete response (CR), 22
achieving a partial response (PR), and one-half achieving stable
disease (SD) or better.16 Other antibodies directed against PD-1
have shown anti-myeloma activity in early clinical results in
RRMM when combined with IMiDs,17,18 suggesting that cetreli-
mab plus the direct on-tumor and immunomodulatory action of
daratumumab may have therapeutic potential among patients with
MM.
The main objectives of this study were to assess the safety, effi-
cacy, pharmacokinetics (PK), and blood biomarker changes associ-
ated with daratumumab with or without cetrelimab among patients
with RRMM.Materials and Methods
Study Design
This was an open-label, multicenter, multiple-phase study to
assess the safety and efficacy of daratumumab with or withoutcetrelimab among patients with RRMM. The study included a
screening phase (28 days before enrollment) followed by 3 treat-
ment phases (Parts 1, 2, and 3), and a follow-up phase. Part 1
comprised the safety run-in phase to evaluate safety and tolerability
based on dose-limiting toxicity (DLT) in cycle 1. In Parts 2 and 3,
patients were to be randomized 1:1 to daratumumab or
daratumumab plus cetrelimab. The study protocol was reviewed
and approved by a local independent ethics committee or institu-
tional review board at each study site. This study was conducted in
accordance with the ethical principles in the Declaration of Helsinki
and was consistent with good clinical practices and applicable reg-
ulatory requirements. Written consent to participate in the study
was obtained before any study-related activity. The study was
registered with ClinicalTrials.gov (NCT03357952); EudraCT
Number 2017-002611-34.
Patients
Adults ( 18 years of age) with documented, measurable RRMM
and who had received at least 3 prior lines of therapy (including a PI
and an IMiD) or were refractory to both a PI and an IMiD were
included. Patients also had evidence of PR or better to at least 1
prior treatment based on investigator’s determination of response by
the International Myeloma Working Group criteria19-21; an Eastern
Cooperative Oncology Group (ECOG) performance status of 0 to
2; hemoglobin 7.5 g/dL; absolute neutrophil count 1.0 109/L;
platelet count  75  109/L ( 50  109/L if  50% of the bone
marrow is infiltrated with MM cells); aspartate aminotransferase and
alanine aminotransferase each2.5 the upper limit of normal; total
bilirubin  2.0  the upper limit of normal; estimated creatinine
clearance  30 mL/min; and corrected serum calcium  14 mg/dL
(or free ionized calcium  6.5 mg/dL). Patients who had received
prior daratumumab treatment were excluded. Additional eligibility
criteria are listed in the Supplementary Appendix (in the online
version).
Treatments
The safety run-in phase had a single treatment arm in which
patients received daratumumab (16 mg/kg intravenously [IV]
weekly for the first 2 cycles [on days 1, 8, 15, and 22; all cycles were
28 days], followed by every other week in cycles 3 to 6 [on days 1
and 15], and then once every 4 weeks on day 1 of each cycle
thereafter) with cetrelimab (240 mg IV on day 2 and day 15 of cycle
1, and then on day 1 and day 15 of all cycles thereafter). Cetrelimab
was given after daratumumab infusion, when applicable. Details on
pre- and post-infusion medications are included in the Supple-
mentary Appendix (in the online version).
In Parts 2 and 3, patients were to receive daratumumab plus
cetrelimab or daratumumab alone with the same dosing regimens as
in Part 1. Daratumumab and cetrelimab toxicities were managed by
dose delay. Study treatment continued until confirmed disease
progression, unacceptable toxicity, or if other discontinuation
criteria were met. Patients who discontinued cetrelimab were given
the option to continue on daratumumab monotherapy until
meeting the discontinuation criteria described above.
During the safety run-in phase, if < 2 patients of the first 6
DLT-evaluable patients experienced a DLT during the first treat-
ment cycle, the selected dose and dose regimens for daratumumabClinical Lymphoma, Myeloma & Leukemia January 2021 - 47
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48 -plus cetrelimab were considered tolerable, and the study could
proceed to Part 2 after approval from the safety evaluation team.
Endpoints and Assessments
The primary objective of the safety run-in (Part 1) was to assess
the safety of daratumumab plus cetrelimab by monitoring the
incidence of adverse events (AEs), including DLTs (primary
endpoint). AEs were assessed according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
Version 4.03. The DLT evaluation period was 28 days starting from
the day of the first dose of study treatment.
DLTs included any of the following events: aspartate amino-
transferase or alanine aminotransferase toxicity (grade 3 lasting 7
days after treatment with corticosteroids, grade 4, or anymeetingHy’s
Law criteria); laboratory abnormality (grade 3 lasting 7 days despite
best supportive care [BSC] or grade 4); any grade  3 event
lasting  7 days despite BSC (or any grade 4 event, except any
grade  3 rash that was asymptomatic/mildly symptomatic and
adequately managed or resolved to asymptomatic/grade 2 within 7
days of supportive therapy); any grade 4 infusion-related reaction
(IRR) occurring within 24 hours of study drug infusion; neutropenia
(grade 4 lasting> 7 days despite BSC, or grade 3 febrile neutropenia,
or sepsis); thrombocytopenia (grade  3 with clinically significant
bleeding or grade 4 lasting > 7 days despite BSC); anemia (grade 4
lasting > 7 days despite BSC); or any grade 5 event.
Safety was assessed by the incidence and severity of AEs, labo-
ratory test results, electrocardiograms, vital sign measurements,
physical examination findings, and ECOG performance status
score. The safety analysis set included all patients who received  1
dose of study drug. AE monitoring was continuous starting from the
date of informed consent until 30 days after the last dose of study
drug, until the start of subsequent anticancer therapy, or study
withdrawal. Drug-related serious AEs (SAEs) were monitored in the
follow-up period (8 weeks after the last dose of study drug and every
12 weeks thereafter).
In Parts 1 and 2, efficacy was assessed by overall response rate
(ORR), defined as the proportion of patients with PR or better.
Disease evaluations were performed every 28 days (3 days) by a
central laboratory until disease progression and assessed according to
International Myeloma Working Group criteria.19-21
PK analyses were performed for patients who received  1 dose
of daratumumab or cetrelimab and who had  1 post-infusion
sample. Samples were to be collected for measurement of serum
concentration of, and possible antibodies against, daratumumab and
cetrelimab before and after infusions on day 1 of cycles 1, 2, 3, 5, 7,
12, 16 (cetrelimab only for this cycle), 24, and every 12 cycles
thereafter, at the end of treatment visit, and at the follow-up visit.
Maximum observed concentration (Cmax), minimum observed
concentration (Ctrough), and coefficient of variation were measured.
All concentrations below the lowest quantifiable concentration were
treated as zero.
Biomarker evaluation was an exploratory endpoint conducted on
samples taken during cycle 1 (day 1, 8, and 15), cycle 2 (day 1 and
15), on day 1 of cycle 4, and at disease progression. Immunophe-
notyping was performed on whole blood by flow cytometry. Values
and changes from baseline at each scheduled visit for absolute
counts (cells/mL) and percentage of total NK cells, CD8þ T cells,Clinical Lymphoma, Myeloma & Leukemia January 2021and B cells in peripheral blood were plotted or summarized. Similar
analyses were performed for total and CD38þ MDSCs, and total
and CD38þ Tregs.
Statistical Analyses
Safety data were provided as the percentage of patients who
experienced  1 AE by treatment group, and comparisons between
treatment groups were to be conducted as appropriate. For response
rates, the number and percentage of patients in each response
category were tabulated, and the ORRs were to be tabulated and
provided with 2-sided 95% confidence intervals for each treatment
group. For time-to-event endpoints (eg, duration of response, PFS,
and OS), Kaplan-Meier estimates were to be provided for each
treatment group; treatment comparisons for PFS and OS were made
by the log-rank test. Cox regression analyses were to provide the
hazard ratio estimates and the 95% confidence intervals to measure
treatment effect. PK and immunogenicity data were to be sum-
marized using descriptive analyses. Biomarker analyses were to be
stratified by clinical covariates or molecular subgroups and analyzed
by the appropriate statistical method depending on the endpoint
(parametric/non-parametric, univariate/multivariate, analysis of
variance, or survival analysis).
Results
On May 25, 2018 (186 days after enrollment of the first patient),
this study was terminated for administrative reasons after 10
patients had enrolled. Termination of this study was a conservative
measure based on results from the phase Ib/II LUC2001 study
(ClinicalTrials.gov Identifier, NCT03023423). LUC2001
evaluated the efficacy and safety of a PD-L1 inhibitor, atezolizumab,
with or without daratumumab among patients with previously
treated advanced or metastatic non‒small-cell lung cancer
(NSCLC). The decision to discontinue LUC2001 occurred at a
planned review by the data monitoring committee and was based on
a lack of observed improved efficacy among patients who received
the combination of daratumumab plus atezolizumab for NSCLC in
that study. The ORR was lower in the daratumumab plus atezoli-
zumab group in LUC2001, but other efficacy endpoints were
similar between treatment groups. Additionally, although there was
an imbalance of deaths in the daratumumab plus atezolizumab
group, these events were not attributed to increased drug-related
toxicity of the combination regimen. Regardless, in response to
these data, the study sponsor stopped further enrollment on all
studies with PD-1 or PD-L1 inhibitors combined with
daratumumab, including the present study.22
Patients
Between November 20, 2017, and September 24, 2018 (data
cutoff), 10 patients were enrolled in the study. In the safety run-in
phase, 9 patients received daratumumab plus cetrelimab. In Part 2
of the study, 1 patient was randomized to receive daratumumab
alone.
Of the 9 patients in the safety run-in phase, 5 (55.6%) were
male, and 8 (88.9%) were white; the median age was 64.0 years
(range, 44-79 years) (Table 1). Six (66.7%) of 9 patients had a
baseline ECOG performance status score of 0, and 3 (33.3%) had a
score of 1. Four (44.4%) patients had measurable disease confined
Table 1 Patient Demographic and Disease Characteristics
Characteristic
Safety Run-in (Daratumumab D
Cetrelimab) (n [ 9)
Median (range) age, y 64.0 (44-79)
Male, n (%) 5 (55.6)
Race, n (%)
White 8 (88.9)
Black or African American 1 (11.1)
Ethnicity, n (%)
Not Hispanic/Latino 9 (100.0)
ECOG performance status, n (%)
0 6 (66.7)
1 3 (33.0)




Light chain (Kappa) 1 (11.1)
Negative immunofixation 2 (22.2)




Cytogenetic profile, n (%)
Standard risk 9 (100.0)
Number of lines of prior therapy
Median (range) 3.0 (2-5)
Patients with 3 prior lines, n (%) 5 (55.6)
Patients with> 3 prior lines, n (%) 4 (44.4)
Median (range) time from diagnosis
to first dose, mo
50.6 (16.4-287.0)
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; Ig ¼ immunoglobulin; ISS ¼
International Staging System.
aBy immunofixation or serum free light chain assay.
Yael C. Cohen et alto serum only, with IgG being the most common immunoglobulin
type. All had standard cytogenetic risk. The median time from
initial diagnosis to the first dose of study treatment was 50.6 months
(range, 16.4-287.0 months). All 9 patients were previously treated
with PIs plus an IMiD, dexamethasone, and alkylating agents; 2
were previously treated with anthracyclines. Eight (88.9%) patients
had previously received autologous stem cell transplant and 2
(22.2%) received prior radiotherapy. The patient in Part 2 was a
43-year-old white male with a baseline ECOG performance status
score of 0 and standard cytogenetic risk (see Supplemental Table 1
in the online version).
All 10 patients enrolled received  1 dose of any study drug. All
9 patients in the safety run-in cohort discontinued participation in
the study owing to administrative closure and were given the option
to receive daratumumab monotherapy. At the time of data cutoff, 5
(55.6%) patients in the safety run-in phase had discontinued
treatment owing to progressive disease, and 4 (44.4%) were
continuing on daratumumab monotherapy. The median follow-up
in the safety run-in phase was 6.7 months (range, 4.2-7.0 months)at the time when all 9 patients in the safety run-in phase were
withdrawn from the study. The patient who enrolled in Part 2
withdrew consent 7 days after receiving the first daratumumab dose,
with a follow-up time of 0.3 months. Figure 1 shows a summary of
patient disposition and treatment allocation at study termination.
Study Drug Exposure
In the safety run-in phase, the median number of daratumumab
infusions was 16.0 (range, 3-18), and the median number of
cetrelimab infusions was 7.0 (range, 2-13). The median number of
treatment cycles was 7.0 (range, 1-8) and the median duration of
treatment was 5.7 months (range, 0.5-7.0 months). The median
relative dose intensity was 100% (range, 74.9%-102.7%) for dar-
atumumab and 88.9% (range, 75.0%-100%) for cetrelimab.
Efficacy
Among the 9 evaluable patients (all safety run-in), the ORR was
44.4%; 3 patients had a best response of very good partial response
(VGPR), and 1 had a PR. Time to response among the 4 patients
with VGPR or PR ranged from 30 to 57 days. There were no CRs.
Of the remaining patients, the best responses were SD (n ¼ 4) and
PD (n ¼ 1). There were 4 events of disease progression occurring at
1.0, 3.9, 5.1, and 5.6 months among patients with a best response
of PD (n ¼ 1), SD (n ¼ 2), and VGPR (n ¼ 1). All patients were
alive at the end of the study.
Adverse Events
All 10 patients enrolled experienced at least 1 treatment-emergent
AE (TEAE) (Table 2 and Supplemental Table 2 in the online
version); however, no DLTs were reported in the safety run-in
phase. Among patients in the safety run-in phase, the most com-
mon TEAE was neutropenia, followed by thrombocytopenia, ane-
mia, fatigue, myalgia, nausea, and vomiting (3 [33.3%] patients
each). Grade 3 or 4 TEAEs occurred in 6 (66.7%) patients in the
safety run-in phase. The majority of the grade 3 or 4 TEAEs were
hematologic AEs, including neutropenia, febrile neutropenia,
thrombocytopenia, anemia, leukopenia, and lymphopenia. Three
patients in the safety run-in phase had an SAE: 1 patient had grade
3 acute kidney injury (not considered related to treatment), 1 pa-
tient had grade 2 autoimmune encephalitis (an immune-mediated
reaction possibly related to cetrelimab), and another patient had
grade 3 febrile neutropenia and 2 septic shock events (one of grade 3
and another of grade 4 per investigator assessment; both grade 4 per
Common Terminology Criteria for Adverse Events, V4.0; all SAEs
in this patient were possibly related to daratumumab based on
temporal association with study drug administration). The patient
with grade 2 autoimmune encephalitis was hospitalized for cognitive
deficits and behavioral changes (“déjà vu”). Laboratory tests showed
polyclonal bands in the cerebrospinal fluid and ruled out infection.
Electroencephalography with sleep deprivation failed to demon-
strate epileptiform activity, but showed moderate left fronto-
temporal slowness. The patient received treatment with intravenous
immunoglobulin and corticosteroids; after several days, the event
was reported as resolved and the patient discharged. There were no
deaths or discontinuation of study treatment owing to AEs.
IRRs occurred in 7 (77.8%) patients in the safety run-in phase.
Most IRRs were grade 1 or 2, with no single event occurring inClinical Lymphoma, Myeloma & Leukemia January 2021 - 49
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) Diagram
Table 2 Treatment-emergent Adverse Events
Patients, n (%)
Safety Run-in (Daratumumab
D Cetrelimab) (n [ 9)
Any TEAEs 9 (100.0)
Related to daratumumab 9 (100.0)
Related to cetrelimab 8 (88.9)
Grade 3 or 4 TEAE 6 (66.7)
Grade 5 TEAE 0
Leading to discontinuation 0
Any serious TEAE 3 (33.3)
Related to daratumumab 1 (11.1)
Related to cetrelimab 1 (11.1)















Infusion-related reactions 7 (77.7)
Abbreviation: TEAE ¼ treatment-emergent adverse event.
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50 -more than 2 patients (chills and cough in 2 [22.2%] patients each).
One patient had a grade 3 IRR of dyspnea, and there were no grade
4 or 5 IRRs. None of the IRRs were deemed related to cetrelimab.
No new malignancies were reported during the study, and no pa-
tients were positive for antibodies to daratumumab or cetrelimab.
Pharmacokinetics
Nine patients from the safety run-in phase were included in the
PK-evaluable population for daratumumab and cetrelimab. The
mean daratumumab Cmax after the first dose (cycle 1 day 1 post-
dose) was 304.99 mg/mL (SD, 60.0 mg/mL) (Figure 2A). Accu-
mulation of daratumumab continued through the first 9 doses of
weekly dosing (the last PK sampling time point in weekly dosing),
resulting in a 3.3-fold increase in mean daratumumab concentration
to a Cmax of 1014.53 mg/mL (SD, 127.6 mg/mL) at cycle 3 day 1.
The mean cycle 3 day 1 pre-dose Ctrough after 8 weekly doses was
706.39 mg/mL (SD, 104.1 mg/mL). Moderate interpatient vari-
ability for daratumumab exposure (w30% coefficient of variation
for post-dose) was observed.
The mean cetrelimab Cmax after the first dose (cycle 1 day 2 post-
dose) was 54.95 mg/mL (SD, 12.2 mg/mL) (Figure 2B). The mean
observed Ctrough for cetrelimab was 79.67 mg/mL (SD, 26.2 mg/mL)
at cycle 3 day 1 (n ¼ 6 patients). The mean Ctrough at cycle 5 day 1
upon reaching steady state after 8 weekly doses was 101.31 mg/mL
(SD, 4.2 mg/mL) (n ¼ 2 patients). Moderate inter-patient variability
for cetrelimab exposure (w30% coefficient of variation for post-
dose) was observed.
Biomarkers
A decrease in NK cells post-treatment was observed
(Figure 3A), providing further evidence that NK cells express
CD38 and are sensitive to daratumumab-mediated depletion as aClinical Lymphoma, Myeloma & Leukemia January 2021
Figure 2 Mean and Standard Deviation Serum Peak and Trough Concentrations of (A) Daratumumab and (B) Cetrelimab in the
PK-Evaluable Analysis Set
Abbreviations: C ¼ cycle; D ¼ day; EOT ¼ end of treatment; PK ¼ pharmacokinetic; post ¼ post-dose; pre ¼ pre-dose.
Yael C. Cohen et alpharmacodynamic biomarker. CD38þ monocytic MDSCs and
CD38þ Tregs were also sensitive to daratumumab, showing
depletion in the first 2 treatment cycles (Figure 3B and C,
respectively). The number of CD8þ T cells increased at
approximately cycle 4 (Figure 3D).
Discussion
This multiple-phase study examined the safety and efficacy of
daratumumab as combination therapy with cetrelimab in heavily
pre-treated patients with RRMM, but the study was terminated by
administrative closure. Owing to the relatively short median follow-
up period ( 6.7 months) and the limited number of evaluable
patients, most planned efficacy analyses were not performed.
Nevertheless, the safety profiles of daratumumab and cetrelimab
were generally consistent with their previously described safety
profiles.4,23-26
Daratumumab leads to deep and durable responses as mono-
therapy or combination therapy with standard-of-care regimens
for patients with RRMM, or as combination therapy for
NDMM.4,27-31 As monotherapy for RRMM among heavily pre-
treated patients, daratumumab was associated with an ORR of
31.1%.4 When combined with standard-of-care regimens forRRMM or NDMM, the ORRs were generally higher and ranged
from 84% to 93%.27-31 Although the ORR (44.4%) in the present
study is generally consistent with response rates seen with
daratumumab monotherapy, comparison to previous trials should
be considered carefully owing to the limited follow-up time and
small number of evaluable patients.
PK analyses of daratumumab in this study, including peak and
trough serum concentrations, were comparable to those observed in
prior studies of daratumumab,32 and the combination of dar-
atumumab with cetrelimab did not appear to alter the PK of dar-
atumumab. Also consistent with previous data for daratumumab
therapy,32,33 no patients were positive for antibodies to
daratumumab, and no patients were positive for antibodies to
cetrelimab.
Although the biomarker analysis was limited by the number of
evaluable samples, patients who received daratumumab plus cetre-
limab showed a decrease in NK cells, CD38þ MDSCs, and CD38þ
Tregs that is consistent with the known sensitivity of these cell
populations to daratumumab.10 Evaluation of total CD8þ T-cell
numbers at baseline and post-treatment with daratumumab in
combination with cetrelimab showed an increase in absolute counts
of CD8þ T cells around cycle 4. This observation is also consistentClinical Lymphoma, Myeloma & Leukemia January 2021 - 51
Figure 3 Immunophenotyping of Peripheral Blood Samples as Assessed by Flow Cytometry Among Patients in the Safety Run-in
Phase. (A) Median Total NK Cells (Absolute Count) in Blood Over Time. (B) Median Percent of CD38D Monocytic MDSCs
of Total MDSCs in Blood Over Time. (C) Median Percent of CD38D Tregs of Total Tregs in Blood Over Time. (D) Median Total
CD8D T Cells (Absolute Count) in Blood Over Time
Abbreviations: BL ¼ baseline; C ¼ cycle; D ¼ day; EOT ¼ end of treatment; MDSC ¼ myeloid-derived suppressor cell; NK ¼ natural killer; Tregs ¼ regulatory T cells.
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52 -with previous clinical data that showed daratumumab increases
absolute counts of CD8þ T cells.10
Checkpoint inhibitors have recently emerged as a highly prom-
ising type of immunotherapy for the treatment of a variety of ma-
lignancies. The pre-clinical finding of high PD-L1 expression in
malignant plasma cells, coupled with evidence suggesting a role for
PD-L1 in the development of myeloma clonal resistance and
relapse, drove the field toward pursuing immune checkpoint
inhibitors in myeloma.13-15,34 Other studies have examined anti‒
PD-1 antibodies as monotherapy or as part of combination therapy
in patients with MM. The phase Ib KEYNOTE-013 study evalu-
ated the safety and efficacy of pembrolizumab, a humanized anti‒
PD-1 antibody, as monotherapy for patients with RRMM. In
KEYNOTE-013, the ORR was 0% with 56.7% (17/30) of patients
achieving SD after a median follow-up of 19.9 months.35 Similarly,
the anti‒PD-1 antibody nivolumab showed limited therapeutic
benefit as monotherapy or combination therapy with ipilimumab in
patients with RRMM, with no patients achieving an objective
response.36,37Clinical Lymphoma, Myeloma & Leukemia January 2021In these studies of anti‒PD-1 antibodies as monotherapies, no
overt safety issues were reported, although these analyses were
among a relatively small number of patients.35,36 In the LUC2001
study of daratumumab plus the PD-L1 inhibitor atezolizumab in
NSCLC, nearly all patients experienced a TEAE.38 Serious TEAEs
were more frequent in LUC2001 (occurring in 47.7% of patients)
than in the current study of daratumumab with cetrelimab (33.3%
of patients), but the clinical significance of this difference is unclear.
Early phase studies of pembrolizumab in combination with
standard-of-care regimens for myeloma showed promising re-
sults,17,18 but the therapeutic benefit of PD-1 inhibition for RRMM
was called into question following results from the randomized phase
III KEYNOTE-183 study.39 In KEYNOTE-183, slightly more pa-
tients died in the pembrolizumab/pomalidomide/dexamethasone
group versus the pomalidomide/dexamethasone alone group (23%vs.
17%, respectively, after a median follow-up of 7.8 vs. 8.6 months).
Moreover, deaths in the pembrolizumab/pomalidomide/dexameth-
asone groupwere disproportionately owing to AEs compared with the
control group (n ¼ 13 vs. n ¼ 3, respectively), and the study was
Yael C. Cohen et alended early owing to the unfavorable benefit-to-risk profile.39 Simi-
larly, the phase III KEYNOTE-185 study of pembrolizumab/lenali-
domide/dexamethasone in transplant-ineligible patients with
NDMMwas terminated early owing to an imbalance in deaths in the
pembrolizumab-combination group versus the control group.40
It is unclear whether the increased deaths observed in the
KEYNOTE-183 and KEYNOTE-185 studies of pembrolizumab-
combination therapy would also occur for the combination of
daratumumab with an anti‒PD-1 antibody, as daratumumab has a
different mechanism of action than the IMiD drug partners tested
with pembrolizumab in KEYNOTE-183 and KEYNOTE-185.
The efficacy and safety of PD-L1 inhibitors have also come under
scrutiny, with several studies being placed on partial holds or sus-
pended. Enrollment was halted or suspended for the phase II
FUSION MM-003 and FUSION MM-005 studies examining
durvalumab with daratumumab in patients with RRMM, following
advisement by the United States Food and Drug Administration
based on the risks identified in other clinical trials evaluating PD-(L)1
inhibitors for the treatment of MM.41
Although the current study showed that combination therapy of
daratumumab and cetrelimab did not cause DLTs, complete effi-
cacy and PK analyses were limited for several reasons. Termination
of the study owing to administrative closure resulted in a relatively
small study population with a short treatment duration and follow-
up. Additionally, as the planned Parts 2 and 3 of the study were not
completed, there was no comparator arm. These limitations prevent
meaningful interpretation of the efficacy and PK data.Conclusion
Early closure of this study hindered the evaluation of efficacy, and
prevented a complete analysis of safety, PK, and biomarkers.
However, no new safety concerns were identified with the combi-
nation of daratumumab plus cetrelimab relative to the individual
therapies, and no AEs led to treatment discontinuation or death.
Further investigations into combination therapies including
daratumumab plus PD-(L)1 inhibitors in MM may be warranted.
Clincial Practice Points
 Improved treatment options are needed for patients with
RRMM.
 Data from pre-clinical and early-phase clinical studies of PD-(L)1
inhibitors suggest that cetrelimab plus daratumumab would have
therapeutic potential for patients with RRMM.
 This study evaluated daratumumab with or without cetrelimab
in patients with RRMM who failed on  3 prior lines of therapy
(including a PI and an IMiD) or who were refractory to both.
 There were no DLTs in the safety run-in phase of the study, and
no new safety concerns were identified.
 The study was terminated for administrative reasons shortly after
the randomized phase began, limiting the complete evaluation
on efficacy, safety, PK, and changes in biomarkers.Acknowledgments
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ADDITIONAL METHODS
Additional Eligibility Criteria
Key inclusion criteria were: age  18 years with documented,
measurable relapsed or refractory multiple myeloma (MM) and had
received at least 3 prior lines of therapy (including a proteasome in-
hibitor [PI] and an immunomodulatory agent [IMiD]) or were re-
fractory to both a PI and an IMiD. Patients also had evidence of partial
response or better to at least 1 prior treatment based on investigator’s
determination of response by the International Myeloma Working
Group criteria,19-21 an Eastern Cooperative Oncology Group perfor-
mance status of 0 to 2; hemoglobin  7.5 g/dL; absolute neutrophil
count  1.0  109/L; platelet count  75  109/L ( 50  109/L
if  50% of the bone marrow is infiltrated with MM cells); aspartate
aminotransferase and alanine aminotransferase each  2.5  the
upper limit of normal; total bilirubin  2.0  upper limit of normal;
estimated creatinine clearance  30 mL/min; and corrected serum
calcium  14 mg/dL (or free ionized calcium  6.5 mg/dL).
Key exclusion criteria were: prior treatment with daratumumab or
other anti-CD38 therapies or antieprogrammed death receptor-1/
programmed death-ligand 1 therapies; antimyeloma therapies
within 2 weeks, except emergency use of a short course of cortico-
steroids (equivalent to dexamethasone 40 mg/day for  4 days) for
palliative treatment prior to the first administration of study treat-
ment; allogenic stem cell transplant (SCT) at any time or autologous
SCT within 12 weeks of the first administration of study treatment;
systemic radiotherapy within 14 days prior to the first dose of study
treatment; clinical signs of meningeal involvement of MM; known
chronic obstructive pulmonary disease with forced expiratory volume
in 1 second < 50% of predicted normal; known moderate or severe
persistent asthma within the past 2 years or uncontrolled asthma;
seropositivity for HIV, hepatitis B, or hepatitis C infection; clinically
significant cardiac disease; history of malignancy other than MM
within 2 years prior to the first dose of study therapy administration
(except squamous and basal cell skin cancer and carcinoma in situ of
the cervix); known allergies/hypersensitivity/intolerance to mannitol,
corticosteroids, monoclonal antibodies, or human proteins or their
excipients, or known sensitivity to mammalian-derived products;
prior diagnosis of autoimmune disease; and vaccination with live
attenuated vaccines within 4 weeks before the first dose of study
therapy. Patients were also not permitted to have planned SCT prior
to progression of disease on this study.Pre- and Post-infusion Medications
Pre-infusion medications were administered to patients who
received daratumumab to manage infusion-related reactions (IRRs).
Pre-infusion medications were administered approximately 1 hour
before the daratumumab infusion and included acetaminophen 650
to 1000 mg intravenously (IV) or orally (PO), diphenhydramine 25
to 50 mg IV or PO or equivalent antihistamine, and methylpred-
nisolone 100 mg IV or PO or equivalent for the first 2 doses and
60 mg for subsequent doses (in the absence of IRRs in the first 2
doses). A leukotriene inhibitor (montelukast 10 mg PO) was
optional and may have been administered up to 24 hours before the
daratumumab infusion. Post-infusion medication included meth-
ylprednisolone 20 mg PO or equivalent on the 2 days after each
daratumumab dose (oral corticosteroids could be given per inves-
tigator discretion after the first 3 doses). Patients with a higher risk
of respiratory complications (eg, patients with mild asthma or pa-
tients with chronic obstructive pulmonary disease who have a forced
expiratory volume in 1 second < 80%) could be given diphenhy-
dramine or equivalent on the first and second day after each infu-
sion, short-acting b2-adrenergic receptor agonist such as albuterol
aerosol, and control medications for lung disease, as needed. If the
at-risk patient experienced no major IRRs after 4 doses of study
treatment, these post-infusion medications could be waived at the
investigator’s discretion.
Additional Results
Single Randomized Patient in Part 2
The patient in Part 2 was a 43-year-old white male with a
baseline Eastern Cooperative Oncology Group performance status
score of 0, IgG disease isotype, standard cytogenetic risk, and a time
from initial diagnosis to the first dose of study treatment of 52.2
months (see Supplemental Table 1 in the online version). The
patient was previously treated with a PI inhibitor plus an IMiD,
corticosteroids, alkylating agents, and had received autologous SCT.
The patient who enrolled in Part 2 withdrew consent 7 days after
receiving the first daratumumab dose, with a follow-up time of 0.3
months. This patient received 2 of 4 planned daratumumab in-
fusions at 100.9% relative dose intensity in the first cycle over 0.3
months.
The patient enrolled in Part 2 was not evaluable for disease
response.Clinical Lymphoma, Myeloma & Leukemia January 2021 - 54.e1
Supplemental Figure 1 Immunophenotyping of Peripheral Blood Samples as Assessed by Flow Cytometry in the Safety Analysis Set
(all Patients). (A) Median Total NK Cells (Absolute Count) in Blood Over Time. (B) Median Percent of CD38D
Monocytic MDSCs of Total MDSCs in Blood Over Time. (C) Median Percent of CD38D Tregs of Total Tregs in
Blood Over Time. (D) Median Total CD8D T Cells (Absolute Count) in Blood Over Time
Abbreviations: BL ¼ baseline; C ¼ cycle; D ¼ day; EOT ¼ end of treatment; MDSC ¼ myeloid-derived suppressor cell; NK ¼ natural killer; Tregs ¼ regulatory T cells.
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Supplemental Table 1 Patient Demographic and Disease Characteristics
Characteristic
Safety Run-in (Daratumumab D





Median (range) age, y 64.0 (44-79) 43.0 64.0 (43-79)
Male, n (%) 5 (55.6) 1 (100.0) 6 (60.0)
Race, n (%)
White 8 (88.9) 1 (100.0) 9 (90.0)
Black or African American 1 (11.1) 0 1 (10.0)
Ethnicity, n (%)
Not Hispanic/Latino 9 (100.0) 1 (100.0) 10 (100.0)
ECOG performance status, n (%)
0 6 (66.7) 1 (100.0) 7 (70.0)
1 3 (33.0) 0 3 (30.0)
Type of myeloma, n (%)a
IgG 3 (33.3) 1 (100.0) 4 (40.0)
IgA 2 (22.2) 0 2 (20.0)
IgM 1 (11.1) 0 1 (10.0)
Light chain (Kappa) 1 (11.1) 0 1 (10.0)
Negative immunofixation 2 (22.2) 0 2 (20.0)
ISS disease stage, n (%)
I 5 (55.6) 0 5 (50.0)
II 3 (33.3) 0 3 (30.0)
III 1 (11.1) 1 (100.0) 2 (20.0)
Cytogenetic profile, n (%)
Standard risk 9 (100.0) 1 (100.0) 10 (100.0)
Number of lines of prior therapy
Median (range) 3.0 (2-5) 3 3.0 (2-5)
Patients with  3 prior lines, n (%) 5 (55.6) 1 (100.0) 6 (60.0)
Patients with > 3 prior lines, n (%) 4 (44.4) 0 4 (40.0)
Median (range) time from diagnosis to
first dose, mo
50.6 (16.4-287.0) 52.2 51.4 (16.4-287.0)
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; Ig ¼ immunoglobulin; ISS ¼ International Staging System.
aBy immunofixation or serum free light chain assay.
Yael C. Cohen et al
Clinical Lymphoma, Myeloma & Leukemia January 2021 - 54.e3
Supplemental Table 2 Treatment-emergent Adverse Events
Patients, n (%)
Safety Run-in (Daratumumab D





Any TEAEs 9 (100.0) 1 (100.0) 10 (100.0)
Related to daratumumab 9 (100.0) 0 9 (90.0)
Related to cetrelimab 8 (88.9) ‒ 8 (80.0)
Grade 3 or 4 TEAE 6 (66.7) 1 (100.0) 7 (70.0)
Grade 5 TEAE 0 0 0
Leading to discontinuation 0 0 0
Any serious TEAE 3 (33.3) 0 3 (30.0)
Related to daratumumab 1 (11.1) 0 1 (10.0)
Related to cetrelimab 1 (11.1) 0 1 (10.0)
TEAEs reported in  20% of patients
Neutropenia 4 (44.4) 0 4 (40.0)
Thrombocytopenia 3 (33.3) 1 (100.0) 4 (40.0)
Anemia 3 (33.3) 0 3 (30.0)
Fatigue 3 (33.3) 0 3 (30.0)
Myalgia 3 (33.3) 0 3 (30.0)
Nausea 3 (33.3) 0 3 (30.0)
Vomiting 3 (33.3) 0 3 (30.0)
Asthenia 2 (22.2) 0 2 (20.0)
Chills 2 (22.2) 0 2 (20.0)
Cough 2 (22.2) 0 2 (20.0)
Diarrhea 2 (22.2) 0 2 (20.0)
Hypertension 2 (22.2) 0 2 (20.0)
Lymphopenia 2 (22.2) 0 2 (20.0)
Paresthesia 2 (22.2) 0 2 (20.0)
Infusion-related reactions 7 (77.7) 0 7 (70.0)
Abbreviation: TEAE ¼ treatment-emergent adverse event.
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